अApnaFunda

LENSKART SOLUTIONS LIMITED (LENSKART)

Retail Trade · Specialty Stores · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.63 / 100
Profitability 62Balance sheet 63
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.76 / 100
Price 92Earnings 60

Passes these screensHigh MomentumNear 52-week high

Share price

Closing priceAdjusted for splits and bonus issues.

₹718.8 latest close · +34.9% over the last 90 sessions

₹600₹700Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹600₹700Jul 3Sep 4Nov 9

₹718.8 month-end · +75.1% over 12 months

₹400₹500₹600₹700Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹400₹500₹600₹700Nov '25May '26Nov '26

52-week range ₹356.10 to ₹762.75 · 1-year volatility 35.0%

Was the rally earned?

+75%share price, 1 yearMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 86.4x to 162.3x); per-share earnings took off 9 points.
  • The share count rose 94%.
Net profit growth: +80 pts. Points of the price return explained by net profit growing (or shrinking).+80 ptsNet profit growthP/E change: +85 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+85 ptsP/E changeShare count change: −89 pts. Points of the price return explained by the share count changing. More shares count against the price.−89 ptsShare count changeShare price: +75%+75%Share priceNet profit growth: +80 pts. Points of the price return explained by net profit growing (or shrinking).+80ProfitP/E change: +85 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+85P/EShare count change: −89 pts. Points of the price return explained by the share count changing. More shares count against the price.−89SharesShare price: +75%+75%Share price
Net profit growth+80 ptsNet profit rose about 81%, which lifts the price.
P/E change+85 ptsThe P/E rose from 86.4x to 162.3x, which lifts the price.
Share count change-89 ptsShare count rose 94%, which lowers the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with AVENUE SUPERMARTS LTD DMART

How rough has the ride been?

Maximum drawdown-14.6%recovered 2026-07
1-year volatility35.0%annualised
Volume spikes4last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−5%−10%−15%2026−14.6% 0%−5%−10%−15%2026−14.6%
Most recent volume spikes

2026-11-05: 5.2x the 50-day median, price +4.2% that day

2026-09-21: 7.8x the 50-day median, price -3.3% that day

2026-08-31: 22.7x the 50-day median, price +4.1% that day

Where does it rank among Retail Trade peers?

Each cell is the company's percentile rank among its Retail Trade peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE36th▲ 9 pts vs a year ago
  • Op. margin88th▲ 3 pts vs a year ago
  • Revenue growth83rd
  • EPS growth23rd
  • Debt/equity ↓53rdflat vs a year ago
  • Cash cycle ↓83rd▲ 22 pts vs a year ago
  • P/E ↓9th▼ 24 pts vs a year ago
  • 12M momentum96th

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Retail Trade sector page Watch it move against Retail Trade in the Observatory

What is the price implying?

~42%annual earnings growth implied by the price

At a P/E of 162.3x, the price would imply about 42.1%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Retail Trade The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹718.80
P/E
162.3x
ROCE
8.0%
Market Cap
₹1.25L cr
Revenue (TTM)
₹9634 cr
P/S
13.0x
P/B
14.3x
ROE
8.8%
Operating Margin
22.0%
Debt / Equity
0.4x
Promoter Holding
17.5%
12M Momentum
75.1%

52-week range

₹356.10₹762.75
89% of the way from its 52-week low to its high

Price risk

1Y volatility
35.0%
Beta vs sector
1-year daily
0.59

Balance sheet & cash

Interest cover
operating profit ÷ interest
5.6x
Cash from profit, 3Y
operating cash flow ÷ net profit
4.30x
Share count, 1Y
+125.3%

Are profits backed by cash?

3 of 5checks within range2 near a threshold
Other income reliance21%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 21.1%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 26.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion4.30xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 4.30x (cash from operations ₹3,388 cr, net profit ₹788 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow3 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress1% of fixed assetsWithin range

Capital work-in-progress is 1% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

What happened next to similar setups

−7.8%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like LENSKART SOLUTIONS LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −19% to +13% vs the market, against −4% for all non-financial companies in the same months.
  • The gap against the base rate (−3.7%, 80% range −14.6% to +4.0%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
KAYNES · Sep 2025: −50.6% vs market
THERMAX · May 2024: −40.4% vs market
BIOCON · May 2020: −37.2% vs market
FLUOROCHEM · Sep 2022: −33.4% vs market
ERIS · Aug 2025: −33.1% vs market
TORNTPHARM · Apr 2020: −33.0% vs market
GENUSPOWER · Nov 2024: −31.2% vs market
DALBHARAT · Mar 2021: −23.8% vs market
GODREJPROP · May 2024: −23.2% vs market
BATAINDIA · Jul 2022: −22.8% vs market
CIPLA · Sep 2020: −22.4% vs market
FORTIS · Oct 2025: −20.6% vs market
SUNPHARMA · May 2020: −19.1% vs market
MEDANTA · Apr 2024: −18.5% vs market
VIPIND · Jun 2022: −18.4% vs market
UNOMINDA · Dec 2021: −17.9% vs market
DLF · Jan 2020: −17.6% vs market
SHREECEM · Jan 2020: −16.9% vs market
CHALET · Aug 2025: −16.9% vs market
MAXHEALTH · Jul 2025: −16.3% vs market
ZYDUSWELL · Mar 2020: −15.6% vs market
ANANTRAJ · Oct 2024: −15.2% vs market
TRENT · Jan 2020: −11.6% vs market
LODHA · Jun 2024: −9.8% vs market
INDHOTEL · Nov 2024: −9.7% vs market
TITAN · Feb 2022: −5.9% vs market
NH · Feb 2020: −5.0% vs market
ZYDUSLIFE · Jul 2020: −3.7% vs market
CARTRADE · Feb 2025: −0.2% vs market
SAFARI · May 2023: +0.9% vs market
TATACONSUM · Aug 2020: +2.0% vs market
SYNGENE · Apr 2020: +7.6% vs market
SRF · Apr 2020: +8.3% vs market
POLICYBZR · Aug 2024: +8.4% vs market
KIMS · May 2025: +8.5% vs market
ANURAS · Sep 2025: +9.6% vs market
ASTERDM · Sep 2025: +10.6% vs market
METROBRAND · Dec 2022: +13.4% vs market
ULTRACEMCO · Mar 2020: +15.5% vs market
PHOENIXLTD · Jul 2022: +20.3% vs market
ETERNAL · Jun 2024: +29.0% vs market
APOLLOHOSP · Feb 2020: +29.4% vs market
RADICO · Apr 2025: +30.7% vs market
POWERINDIA · Jun 2024: +51.8% vs market
VBL · Nov 2022: +54.6% vs market
ADANIENT · Mar 2021: +58.1% vs market
NAVINFLUOR · Oct 2025: +61.3% vs market
ACUTAAS · Feb 2025: +68.7% vs market
LAURUSLABS · Oct 2025: +166.6% vs market
MTARTECH · Oct 2025: +183.6% vs market
Similar setups −7.8%All companies −4.1%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median
−7.8%
All companies' median
−4.1%
Beat the market
42% vs 45%

50 past situations · 50 companies · 30 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
TRENT
Retail Trade
Jan 2020 202x11% +67%−2% −12%
LAURUSLABS
Health Technology
Oct 2025 101x9% +94%−2% +167%
SHREECEM
Non-Energy Minerals
Jan 2020 80x13% +46%−4% −17%
FORTIS
Health Services
Oct 2025 89x12% +64%−7% −21%
MAXHEALTH
Health Services
Jul 2025 113x15% +35%−4% −16%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
TATACONSUM
Consumer Non-Durables
Aug 2020 110x9% +91%−3% +2%
TORNTPHARM
Health Technology
Apr 2020 91x13% +31%−8% −33%
BIOCON
Health Technology
May 2020 47x13% +31%−2% −37%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: interest cover, drawdown from 12-month high and 12-month momentum. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to LENSKART SOLUTIONS LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

Health Services
66%similar
P/Emarket cap
BIOCONBIOCON
Health Technology
65%similar
P/Emarket cap
Health Services
65%similar
revenuedebt/equity
Health Services
59%similar
promoter holdingrevenue
Consumer Durables
57%similar
operating marginvolatility
Retail Trade
51%similar
revenuemarket cap
TRENTTRENT
Retail Trade
32%similar
debt/equitymarket cap
Retail Trade
30%similar
volatilityrevenue

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

7 events since Dec '25

  1. NovSharesShare count is up 125.3% over 12 months.
  2. NovPriceVolume reached 5.2x its 50-day median on 2026-11-05; price +4.2% that day.
  3. SepInstitutionsFII + DII holding rose 16.6 pts over 2 quarters to 36.3%.
  4. AugPriceVolume reached 22.7x its 50-day median on 2026-08-31; price +4.1% that day.
  5. MayPriceVolume reached 29.0x its 50-day median on 2026-05-08; price +0.3% that day.
  6. FebPriceVolume reached 23.6x its 50-day median on 2026-02-12; price +9.7% that day.
  7. DecPriceVolume reached 8.7x its 50-day median on 2025-12-19; price +14.1% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history13 months · 2025-11 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-11162.3x₹9634 cr8.8%8.0%0.4x
2026-10153.1x₹9634 cr8.8%8.0%0.4x
2026-09154.6x₹9634 cr8.8%8.0%0.4x
2026-08168.5x₹8814 cr6.6%8.0%0.4x
2026-07142.8x₹8814 cr6.6%8.0%0.4x
2026-06131.0x₹8814 cr6.6%8.0%0.4x
2026-0593.2x₹8026 cr10.1%6.0%0.5x
2026-0491.8x₹8026 cr10.1%6.0%0.5x
2026-0388.8x₹8026 cr10.1%6.0%0.5x
2026-02110.1x₹7387 cr7.5%6.0%0.5x
2026-0193.7x₹7387 cr7.5%6.0%0.5x
2025-1292.4x₹7387 cr7.5%6.0%0.5x
2025-1186.4x₹7027 cr7.2%6.0%0.5x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback